Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05906992
PHASE3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Sponsor: Celltrion

View on ClinicalTrials.gov

Summary

This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.

Official title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

512

Start Date

2024-01-11

Completion Date

2029-01

Last Updated

2024-05-22

Healthy Volunteers

No

Interventions

BIOLOGICAL

CT-P53

Intravenous(IV) infusion

BIOLOGICAL

US-Ocrevus

Intravenous(IV) infusion

BIOLOGICAL

EU-Ocrevus

Intravenous(IV) infusion

Locations (1)

CT-P53 3.1 investigational site

Poznan, Poland